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Abstract 
Background and Aim: Hepatitis B virus (HBV) infection is associated with an 
increased risk of hepatocellular carcinoma (HCC). The virus encodes a hepatitis B 
virus X protein (HBx) which plays an important trans-activation role in HCC 
development. Recent studies showed that COOH-temiinal truncated HBx was 
frequently observed in liver tumors but not in their adjacent liver tissues, suggesting 
that the truncated HBx mutants may play an important role in hepatocarcinogenesis. 
The aims of this project are to investigate the biological effects of COOH-terminal 
truncated HBx on cell proliferation, cell cycle analysis and cell apoptosis; and to 
identify miRNAs that were induced by fiill-length HBx and COOH-terminal 
truncated HBx in human hepatocyte. Results: PGR amplification of HBx showed that 
COOH-temiinal truncated HBx was detected in 50% of HCC tissues, but not in the 
adjacent non-tumor tissues. Immunochemical staining of the tissue sections 
confirmed their expression. To investigate the biological effects of the 
COOH-truncated HBx mutants, lentivirus expressing full-length HBx, HBxA14 and 
HBxA35 (14 and 35 amino acids deletion at the COOH-terminus) were generated to 
transduce a human non-timiorigenic liver cell line, MIHA. In comparison with a 
mock-infected control, HBxA35 stimulated cell proliferation, whereas full-length 
HBx inhibited cell growth. Cell cycle analysis revealed that HBxA35 promoted S 
phase progression, but full-length HBx attenuated cells at GO/Gl phase and blocked 
Gl/S phase transition. However, HBx and its truncated mutants had no effect on cell 
apoptosis. To identify the differentially expressed miRNA in full-length HBx and 
HBxA3 5-infected cells, miRNA profiling was conducted using Agilent Human 
miRNA Microarray kit (V2) (v. 10.1). A total of 23 miRNAs were deregulated by 
full-length HBx and/or HBxA3 5 by at least 2-fold. Subsequent validation by 
i 
real-time PCR analysis confirmed that 2 miRNAs were commonly down-regulated, 
whereas 4 miRNAs were commonly up-regulated by the two versions of HBx. 
Importantly, miR-146a, miR190 and miR-29c were differentially expressed in 
full-length HBx and HBxA35- infected cells, and were significant down-regulated in 
liver tissues. In summary, we showed the importance of COOH-temiinal truncated 
HBx in HCC and explored the possible linkage between miRNAs and truncated 
HBx-induced hepatocarcinogenesis. Our findings might provide biological insight on 
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Chapter 1 INTRODUCTION 
1.1 Hepatocellular Carcinoma 
1.1.1 Epidemiology 
Liver cancer is the sixth most common cancer worldwide and the third most 
common cause of cancer mortality (Parkin et al.’ 2005). Hepatocellular carcinoma 
(HCC) accounted for around 90% of liver cancers, while cholangiocarcinoma and 
hepatoblastoma contributed to the remaining 10%. The incidence of HCC distributed 
geographically, mainly in Africa, eastern and southeastern Asian. China alone 
accounted for 55% of the global cases. In addition, HCC showed male predominance 
with male to female ratio ranging from 2:1 to 4:1 in most regions, but different age 
distribution varied by sex, geographic region and etiology (Parkin, 2002). 
1.1.2 Etiology 
A number of risk factors had been associated with HCC, including viral 
hepatitis, heavy alcohol consumption (Donato et al, 2002), aflatoxin diet intake 
(Soini et al., 1996), excessive vinyl chloride exposure (Mastraiigelo et al” 2004) and 
use of contraceptive (Malieshwari et a/” 2007). Furthermore, HCC was also 
associated with certain disease states, for instance nonalcoholic fatty liver disease 
(Bugiaiiesi et al,, 2002), obesity, diabetes mellitus (Regimbeau et al, 2004) and 
hereditary hemochromatosis (Hellerbrand et al, 2003). In some cases, two or more 
risk factors co-existed and exerted synergistic effects on HCC development (Marrero 
et al, 2005). 
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Among various risk factors, chronic infection with hepatitis B virus (HBV) or 
hepatitis C vims (HCV) contributed to more than 80% of HCC cases worldwide, and 
it was more prevalence in developing countries than developed countries (Parkin, 
2006). Except Japan, the prevalence of HBV was much higher than HCV in most 
Asian countries (Merican et a!., 2000). In addition, the risk of HCC in HBV-positive 
individuals was 100-fold higher than uninfected individuals (Beasley, et al, 1981). 
Altogether, the epidemiological data suggests an urgent need in conducting 
researches in HBV-related HCC. 
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1.2 Hepatitis B Virus 
1.2.1 The Epidemiology of Hepatitis B Virus Infection 
Two billion people worldwide have been infected with HBV, which caused 
acute and chronic liver disease. The symptom of acute infection might be mild and 
most adults would eventually recover, but approximately 5 to 10%, corresponding to 
350 million people, were unable to clear the virus and became chronically infected 
(Liang. 2009). In addition to HCC, chronic HBV infection could progress to 
worsening disease condition, including compensated cirrhosis, decompensated 
cirrhosis and liver failure. The prevalence of chronic HBV infection imposed a huge 
health and economic burden to the society (Zhiqiaiig et al.’ 2004; Yang et al.’ 2004). 
Nevertheless, the population of HBV carriers could be effectively minimized by 
promoting public awareness of the diseases and adopting vaccination at birth 
(Poovorawan et al” 2009). 
Body serum, semen and saliva are the sources of infectious HBV, but this virus 
could also survive outside the body and remained infectious for at least 7 days 
(Bancroft et al , 1977; Alter et al, 1997; Bond et al, 1981). It was transmitted by 
percutaneous or mucosal exposure to blood or body fluids of infected patients, but 
the mode of transmission varied in different regions. In developing countries, people 
were usually infected at young age through mother-to-child and child-to-child route. 
On the contrary, perinatal transmission through blood transfusion and sexual 
behavior were prevalent in developed countries (CDC. 2005; Frenette et al” 2009). 
Childhood infection was often resulted in chronic hepatitis, while most adults could 
recover from acute infection and developed efficient adaptive immune responses 
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(Fisicaro et al.’ 2009). 
1.2.2 The Morphology and Genome of Hepatitis B Virus 
HBV belongs to a family of DNA virus, called the hepadnavimses. The viron is 
a 42-iini sphere that consists of an outer lipid envelope and an inner core or 
nucleocapid, encompassing HBV genome and the polymerase (Figure 1.1). The viral 
envelope is composed of large，middle and small surface proteins, which are 
synthesized differentially on a single open reading frame containing three in-frame 
start codons. Viral infection is initiated by the interaction between an intact pre-S 
domain of the large envelop protein and a hepatic surface receptor, the 
glycoaminoglycan (GAG) side chains of cell-surface associated heparin sulfate 
proteoglycans (Schulze et al., 2007; Leistner et al., 2008). Being detectable in most 
chronic hepatitis B patients, the viral surface proteins (HBsAg) could be used as a 
marker to monitor the disease progression and to predict the clinical outcomes (Arase 
et al.’ 2006; Yuen et al” 2008). 
HBV consists of a partially double-stranded DNA of 3.2 kb in size, containing 
four overlapping open reading frames that encode S, the surface or envelop gene; P, 
the polymerase gene; C, the core gene; and X, the X gene (Lee, 1997) (Figure 1.2). 
DNA virus replicates through an RNA intermediate by the reverse transcriptase 
function of HBV polymerase, which is covalently attached at the 5’ end of the minus 
stand (Gerlich et al” 1980). A number of licensed antiviral drugs, including 
lainivudine (Dienstag et al., 1999), entacavir (Chang et al.’ 2006), telbivudine (Lai et 
al., 2007), adefovir dipivoxil and tenofovir disoproxil fumarate (Marcellin et al” 
2008), inhibit viral replication by acting as nucleoside analogs that block the catalytic 
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function of HBV polymerase. 
The core protein, also called HBcAg, has the intrinsic property to self-assemble 
into a capid-like structure that encloses viral DNA during replication. Translation 
from another in-frame start codon of the core gene yields a secretary antigen, HBeAg, 
which is not required for replication or acute infection in vivo (Chang et al., 1987). In 
contrast, this antigen may serve as an immunoregulatoiy protein that promotes 
chronicity in nature infection or a target for the inflammatory inniiime response 




Figure 1.1 The schematic structure of hepatitis B virus. HBV is a 
double-shelled viral particle of 42-mii in diameter. The outer envelope is composed 
of large, middle and small surface protein, while the inner core encompassing the 
viral genome and polymerase. 
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Figure 1.2 The genomic structure of HBV. HBV is a partially double-stranded 
DNA virus having four overlapping open reading frames, which encodes X gene, 
preC/C gene, P gene and the preSl/preS2/S gene. 
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1.2.3 HBV Genotypes and Their Significance 
According to the phylogenic analysis of complete viral sequences, HBV can be 
divided into eight genotypes (A to H) based on an intergenotype divergence of >8% 
and different subgenotypes (Ae and Aa in genotype A; Bj and Ba in genotype B; 
genotype Ce and Cs in genotype C) with an intersubgenotype divergence between 
4% and 8% (Norder et aL, 1994; Chan et al,，2005). The distribution of genotypes 
varied geographically and strongly associated with eth nicity. For instance, HBV 
genotype Ce was more prevalent in the Far East (Japan, Korea, and northern China), 
whereas HBV genotype Cs, was more prevalent in Southeast Asia (Vietnam, 
Thailand, Myamiiar, and southern China) (Chan et aL’ 2005). 
The viral genotype had been correlated with some clinical characteristics in 
patients with chronic hepatitis B, including the response to interferon therapy (Wai et 
al, 2002), the rate of HBeAg seroconversion (Chu et al., 2002), the severity of liver 
diseases (Kao et al., 2000) and the risk of HCC (Chan et al” .2004). In a 769 
HBV-positive cohort, patients infected with hepatitis B subgenotype Ce had higher 
risk of HCC when compared to another viral subgenotype Cs and genotype B (Chan 
et a!., 2008). Furthermore，a large scale HBV whole genomic sequencing revealed 
a number of genotype-specific hot-spot mutations associated with HCC, for instance 
C1165T, A1762T and G1764A, T2712C/A/G, and A/T2525C in HBV genotype B; 
T31C，T53C, and A1499G in HBV subgenotype Ce; and G1613A, G1899A, 
T2170C/G, and T2441C mutation in HBV subgenotype Cs (Sung et al.，2008). 
However, the functional significance of these HCC-associated hot-spot mutations is 
still unknown. 
8 
1.3 Hepatitis B Virus X Protein 
HBx acted as a transcriptional transactivator that had been implicated in HCC. It 
is a 154-amino acid protein, with a molecular mass of 17kDa, detectable in both 
HCC tissues and adjacent non-tumor tissues. Depending on its intracellular 
expression level, the subcellular localization of HBx varied differently in the 
cytoplasmic and the nuclear compartment (Doria et al, 1995; Henkler et al., 2001). 
No known DNA binding domain was identified in the HBx protein. However, 
this viral protein could transactivate gene expression through altering different 
signaling transduction pathways, epigenetic modifications and associating with a 
number of transcription factors. Certain oncogenes and tumor suppressor genes were 
frequently deregulated through these mechanisms, suggesting that HBx might be an 
important player in HBV-related HCC. A solid support of this notion was provided 
by an in vivo study demonstrating liver cancer development in transgenic mice 
over-expressing the X protein (Kim et al, 1991). 
The subcellular localization of HBx governs its function as a potent 
transactivator (Majano et a!., 2001). At low expression level, HBx was 
predominantly localized in the nucleus, but it shifted to cytoplasm at elevated level 
(Henkler e( al., 2001). Nuclear localization signal tagged HBx (NLS-HBx) targeted 
to the nucleus and failed to activate AP-1 or N F K B dependent transcription, whereas 
the native HBx stimulated A P - 1 and NFKB dependent transcription. These effects 
were mediated through the Ras-Raf-MAP kinase signaling pathway in the cytoplasm, 
showing the functional importance of HBx subcellular localization (Doria et al., 
1995). 
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1.3.1 HBx Alters Various Signal Transduction Pathways 
HBx is well-characterized for its ability to activate various signal transduction 
pathways, including Ras/MAPK (Benn et al” 1994), Jak-Stat (Lee et al, 1998), 
SAPK/JNK (Diao et a!.., 2001), PI-3K/Akt (Chung et al.,, 2004)，NF-kappaB, and 
FAK (Bouchard et al,’ 2006). Deregulation of these pathways might cause cellular 
transformation and tumor development (Kim et al., 2001). Furthermore, HBx also 
played a role in promoting HBV replication by activating calcium signaling 
pathways involving Pyk2 and Src tyrosine kinases (Bouchard et a!.., 2001). Although 
the cytoplasmic compartmentation of HBx was required to activate a fraction of the 
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Figure 1.3 A network of HBx-mediated transactivation. HBx exerted its 
functions by transactivating a number of signal transduction pathways, including 
calcium signaling pathway, Ras-Raf-MAPK-JNK pathway etc. HBV replication was 
enhanced and gene transcription was altered by HBx. 
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1.3.2 HBx Interacts with Various Transcription Factors and Co-activators 
HBx is not a transcription factor, but it could alter endogenous gene regulation 
and expression by associating with the components of the basal transcription 
machinery (RPB5, TFIIB, TFIIH and TBP), various transcription factors and 
co-activators (Cheong et al.，1995; Qadri et a/.， 1995; Haviv et al, 1996). For 
instance, HBx interacted physically with myc-associated zinc finger protein (MAZ), 
a transcriptional repressor of human telomerase, and enhanced the binding efficacy 
of MAZ to its consensus sequence of the telomerase promoter. By acting as a 
co-repressor of the telomerase promoter, HBx down-regulated the transcription of 
human telomerase, inducing telomerase shortening in hepatoma cell line (Su et al., 
2007). In addition, HBx interacted directly with a co-activator CREB-binding protein 
(CBP)/p300 and promoted the recruitment of p300 to CREB-responsive promoters. 
The increased occupancy of p300 to promoter regions carrying CREB-responsive 
elements stimulated gene expression of iiiterleukin 8 and proliferating cell nuclear 
antigen (Cougot et al” 2007). 
By utilizing the state-of-the-art chromatin immunoprecipitation with microarray 
technology (ChlP-on-chip), a gene network regulated directly by a specific 
transcription factor or indirectly through a transcription factor can be elucidated 
(Cheng et al,, 2006). This approach has been employed to identify the potential 
transcription factors interacting with HBx and the gene network regulated by HBx. A 
recent study has identified 184 direct transcriptional targets of HBx and 144 
transcription factors potentially interacting with HBx were predicted. Of these, 
SMAD4, E2F1 and YYl were validated as the putative transcription factors that 
interacted with HBx (Sung et a!,, 2009). The integrative approach allows better 
12 
understanding of the combinatorial transcription regulated by HBx and a variety of 
transcription factors. 
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1.3.3 HBx Induces Epigenetic Alterations 
DNA methylation of promoter CpG islands leads to gene silencing, an 
epigenetic modification mediated by DNA metliytransferases (DNMT). HBx 
engaged in this epigenetic network by interacting with DNMT3A or histone 
deacetylase 1 (HDACl) directly, and transactivating a number of DMNTs, including 
DNMTl, DNMT3A1 and DNMT3A2 (Park et al., 2007; Zheng et al., 2009). A 
complex regulatory circuit seemed to regulate DNMTl, but not the other DNMTs， 
through the Dl-CDK4/6-pRb-E2Fl pathway (Jung et al, 2007). 
Of the genes regulated by HBx-mediated promoter methylation, interleukin-4 
receptor (IL4R), metallothionetin-lF (MTIF), insulin-like growth factor-3 (lGFBP-3) 
and Cadherin 6 type 2 (CDH6) were studied in details. Epigenetic regulation 
mediated by HBx was a two-way strategy, one involved the direct interaction of HBx 
with DNMT3A, and silenced their transcription by recruiting DNMT3A to the 
promoter of IL4R or MTIF, whereas the other stimulated the transcription of 
IGFBP-3 or CDH6 by associating with DNMT3A and depriving DNMT3A from 
their promoters (Zheng et al., 2009). 
However, the HBx-mediated epigenetic modifications might be interfered by 
other factors, including the viral genotype and the cell line used in the studies, 
leading to an opposite effect of HBx on IGFBP-3 promoter methylation and gene 
transcription (Park et al., 2007; Shon et al., 2009). 
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1.3.4 Identification of COOH-terminal Truncated HBx in Liver Tumors 
Carboxyl (COOH)-temiinal truncated HBx, instead of foil-length HBx, was 
found in a number of primary liver tumor tissues (Tu et al” 2001; Ma et al” 2008). 
The number of amino acids deleted from the C-terminals varied from patients to 
patients. However, no conserved site of HBx truncation was observed and the exact 
mechanism leading to the formation of truncated HBx is still unknown. 
One proposed mechanism involved human AP0BEC3 (apolipoprotein B niRNA 
editing enzyme, catalytic polypeptide 3) cytidine deaminases, which inhibited 
mammary virus replication. It preferentially mediated G-to A hypermutations in the 
HBx region of HBV DNA, causing the formation of a 119 aa C-temiinal truncated 
HBx protein (35-aa deleted) by generating a premature stop-codon (TAA) at 
nucleotide position 359 and 360 (TGG to TAA). Sequencing of HBx in primary liver 
tissues further supported the occurrence of this event (Xu et al., 2007). 
Another possible mechanism leading to COOH-terminal truncated HBx is the 
integration of HBV DNA into the host genome, a frequent event observed in liver 
tissues of chronic hepatitis patients and HCC patients (Shafritz et a]” 1981; 
Murakami et al., 2005). In this regard, HBV integration generated the hybrid 
virus-cell transcripts containing sequences of viral surface gene, the viral enhancer 
and different truncated forms of HBx (Wei et al., 1995). By using Alu-PCR, a natural 
mutant of 27-aa deletion in HBx was identified in the liver tumor (Zhang et al,, 
2008). 
The full-length and COOH-terminal truncated HBx showed distinct biological 
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effects on liver cell culture systems, although they shared a large portion of the 
N-terminal domain. Functional mapping of various COOH-temiinal deleted HBx 
suggested that the last 14-aa was corresponded to be a growth suppressive domain 
(Tu et ciL, 2001). By deleting at least 14-aa from the COOH-terminal, the growth 
suppressive effect induced by the full-length HBx was abrogated, or in some reports, 
it even enhanced cell proliferation. In addition, the apoptotic effect induced by 
full-length HBx was also abolished in COOH-terminal HBx deletion mutants (Ma et 
cil., 2008). However, the deletion might interfere with the traiisactivation domain, 
leading to decrease in transactivation efficacy of HBx deletion mutants (Tu et al., 
2001). Altogether, the biological effects of COOH-terminal truncated HBx seemed to 
be more consistent with the role of HBx in hepatocarcinogenesis. 
16 
1.4 MicroRNAs 
Since the discovery of miRNA (lin-4) in C. elegans, the research in this field 
grew exponentially in recent years (Lee et al” 1993). MiRNAs are 21- 25 nt 
non-coding small RNAs, which have been found in vertebrates, plants, viruses, 
insects, etc. Until 2009, the sequences of 706 human mature miRNAs were 
delineated and over 9000 mature miRNA products were uncovered in 103 species in 
a miRNA registry, miRBase (v. 13.0) (http://mici.oma.sanger.ac.uk/) (Griffiths-Jones 
et ah, 2008). 
MiRNA acts as a posttranscriptional regulator that fine-tunes endogenous gene 
expression. A single miRNA could repress the production of hundreds of proteins, 
but the level of down-regulation was mostly mild (Selbach et al., 2008). These tiny 
molecules could be induced by various environmental stimuli, including temperature 
(Johnston el al., 2009), hypoxia (Fasanaro et al” 2008) and ethanol exposure (Wang 
et al” 2009b). Besides, they had been implicated in various developmental processes, 
cellular differentiation, transformation and cancer development. In embryonic stem 
cells, up-regulation of miR-145 was shown to regulate S0X2, 0CT4 and KLF4, a 
core network of transcription factors that maintain self-renewal and pluripotency (Xu 
et al.’ 2009). 
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1.4.1 Transcriptional Regulation and Biogenesis of MicroRNAs 
Little is known about the promoter regions, regulatory elements and the 
transcription start sites (TSS) that are essential for miRNA synthesis and regulation. 
MiRNA promoters are usually located several hundred base pairs upstream the TSS, 
and are essential for the regulation of their endogenous mature miRNA levels. Some 
miRNAs process their own promoters, whereas the others share the same promoters 
and co-transcript with nearby genes (Ozsolak et al” 2008). One of the most 
extensively studied promoters, miR-21, is located within an intron of a coding gene， 
TMEM49, but they are regulated independently. In silico analysis revealed the 
binding sites of AP-1, p53, STAT3, EST/PUl and E2-box in the enhancer and 
promoter region, and activated AP-1, STAT3 or E2-box have been shown to stimulate 
the transcription of miR-21 (Du et al” 2009; Fujita et al., 2008; Loffler et al., 2007). 
RNA polymerase 11 or III is responsible for transcribing miRNA primary 
transcripts (Pri-miRNA), which are cleaved to liberate a stem-loop miRNA precursor 
(Pre-miRNA) by an RNase III endonuclease called Drosha (Borchert et al., 2006; 
Lee et al,, 2004). The resulting precursor transcript is actively exported out of the 
nucleus by Ran-GTP and the nuclear export receptor, Exportin-5. In the cytoplasm, 
another RNase III endonuclease, Dicer, further cleaves the 60-70 nt pre-miRNA at 
the loop sites, resulting in the formation of a short, double-stranded RNA molecule 
(miRNA::miRNA*). This duplex RNA molecule is composed of a guide strand and a 
passenger strand. The passenger strand is degraded rapidly while the guide strand 
associates with the RNA-induced silencing complex (RISC) to carry out the 
posttranscriptional regulation of its target genes (Figure 1.4) (Bartel, 2004). 
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Acting as a post-transcriptional regulator, miRNA mediates its effects through 
inhibiting translation or inducing degradation of target niRNAs (Selbach et al., 2008). 
The expression level of its target proteins drops with or without an accompany 
reduction in the niRNA levels. Analysis of iiiiRNA-mRNA interaction revealed that 
the miRNA seed region (nucleotide 2- 8) seemed to play a critical role in governing 
its mRNA targets (Lewis et al., 2005). These tiny RNA molecules regulated gene 
expression by partial complementary to the 3’ untranslational region (3'UTR), and in 
some reports, to the coding sequences of the target mRNA transcripts (Fornian et al” 
2008; Tay et aL, 2008). 
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Figure 1.4 Biogenesis of miRNA. Transcription of miRNA is initated by RNA 
polymerase II or III to form a primary miRNA transcript. The transcript is processed 
by Drosha and Dicer to generate the mature miRNA. The functional miRNA stranded 
is selected by RISC and represses translation by interacting with the 3'UTR of target 
messenger RNAs. 
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1.4.2 MicroRNAs and Cancer 
MiRNAs were frequently deregulated in various cancers, including lung, 
prostate, breast, liver cancer (Dalmay et al., 2006). The deregulated miRNAs 
mediated their effects by targeting different oncogenes or tumor suppressor genes, 
leading to abnormal oncogenic phenotypes, including increased proliferation and 
metastastic potential. For instance, down-regulation of miR-145 was frequently 
observed in various cancers, including lung cancer, breast cancer，prostate cancer, 
gastric and colon cancer, and contributed to tumorigenesis by affecting cell growth 
(Dalmay et al, 2006; Schetter et a!.，2008; Takagi et al” 2009). 
Ill addition, miRNA might also play a role in virus-associated cancers. Viral 
infection was usually accompanied with a cascade of host immune responses that 
prevented viral spreading and assist viral clearance (Koyama et a/., 2008). Cellular 
stress response was also arisen on infected cells, and deregulated the endogenous 
gene expression (Jindal et al.，1992). Some viral infected cells differentially 
expressed a subset of cellular miRNAs, which modulated the host immune response 
and enhanced potential for carcinogenesis (Table 1.1). However, the host-virus 
interaction was complicated as viruses could utilize the cellular machinery to 
replicate and express over ten different viral proteins, while the viral proteins might 
alter the endogenous gene expression. 
Like HBV, Human Papillomavirus (HPV), Epstein-BaiT Vims (EBV), Kaposi's 
sarcoma-associated herpesvirus (KSHV) and Human T-lymphotropic virus Type I 
(HTLV-l) were strongly associated with higher incident rates of certain types of 
cancers (Table 1.3) (Parkin, 2006). The vims-related oncogenic transformation might 
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be mediated through the expression of viral oncoproteins that modulated cellular 
miRNA expression. For instance, HPV oncoprotein E6 suppressed miR-34a 
transcription, causing cell proliferation (Wang et al” 2009c) Besides, EBV 
oncoprotein LMPl and HTLV-1 oncoprotein Tax up-regulated miR-146a to modulate 



















































































































































































































































































































































































































































































































































































































































































































































1.4.3 MicroRNAs and HCC 
MicroRNA microarray and PCR-based TaqManty MicroRNA Array were 
commonly used to examine miRNA expression profiles. A panel of deregulated 
miRNAs were identified by comparing the miRNA profiles between liver tumor 
tissues (T) and their matched adjacent nontimior tissues (NT) or normal tissues (N) 
(Table 1.3). A set of distinct miRNAs, including miR-21, miR-182, miR-221, 
miR-222, miR-224 were often up-regulated, while miR-122a and miR-145 were 
down-regulated in HCC (Murakami et al., 2006; Meng et al., 2007; Wong et aL, 
2008a; Wang et al., 2008b). Instead of identifying deregulated miRNAs in HCC, a 
great deal of useful information could be inferred from the profiling data. For 
instance, HCC tumors and the adjacent nontumor livers could be differentiated from 
each other by the expression levels of mir-222 and miR-223 alone (Wong et al.’ 
2008a). Besides, a set of 19 miRNA significantly correlated the disease outcomes, 
and distinguished patients with good survival from those with poor survival (Jiang et 
al.’ 2008). Deregulation of certain miRNAs was also associated with various risk 
factors and oncogene or tumor suppressor gene mutations in HCC (Ladeiro et al., 
2008). 
Though a number of deregulated miRNAs has been identified in profiling 
studies, their biological functions and roles in hepatocarcinogenesis remain largely 
unclear. Identification of miRNA targets remains one of the top challenges in 
microRNA researches. A number of computer programmes, including TargetScan, 
PicTar and MiRanda, were established to predict miRNA targets, but only a few 
miRNAs implicated in HCC development have been thoroughly studied. For 
instance: up-regulation of miR-21 in HCC tissues enhanced tumor cell proliferation, 
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migration and invasion. Phosphatase and tensin homolog (PTEN) was identified to 
be a direct target of miR-21 and mediated the effect of cell invasion (Meng et ai, 
2007). On the other hand, down-regulation of miR-223 was common in HCC tissues. 
Re-expression of miR-223 suppressed cell viability, and possibly, through one of its 
downstream targets Stathmin 1 (STMNl) (Wong et al” 2008a). 
Furthemiore, the role of miRNAs in the issue of high male to female HCC 
incident rate was proposed. MiRNA profiles of male and female HCC tissues were 
compared and a number of gender-specific miRNAs were implicated in contributing 
to higher HCC incident rate in male. Mir-18a was frequently up-regulated in female 
than male HCC tissues. Functional studies revealed that miR-18a targeted estrogen 
receptor 1 gene (ESR1) and stimulated the proliferation of hepatoma cells (Liu et ai.., 
2009). As the gene product, estrogen receptor a , was essential for mediating the 
effects of cellular estrogen, and up-regulation of miR-18a might play a role in 
abolishing the protective effects of estrogen in female leading to HCC development. 
Patients diagnosed with HCC usually had poor prognosis, as most of them were 
identified at advanced stages. The 5-year disease-free survival rate was only 27% 
(Fan et al., 1999), which was attributable to the high recurrent rates in the form of 
intrahepatic metastasis and multicentric occurrence and the poor response to 
chemotherapeutic drugs (Zhu et al., 2006). Poor understanding of the molecular 
mechanism governing tumor metastasis hampers the design of potent 
chemotherapeutic agents. 
In HCC, a set of 20-miRNAs signature that could discriminate the metastasis 
from non-metastasis cases was identified and associated with patient survival. Of 
26 
these, miR-219-U miR-207, miR-338 were up-regulated, while miR-34a; miR-30c-l 
and miR-148 were most down-regulated in metastasis cases (Budhu et al., 2008). 
The metastasis-related miRNAs are different from the HCC deregulated miRNAs, 
suggesting that tumor metastasis may take different molecular pathways. 
An independent study validated that miR-122, a liver-specific miRNA, was 
frequently down-regulated in liver cancers with intrahepatic metastasis. MiR-122 
inhibited cell migration, invasion and tumor independent growth in vitro’ while 
suppressed tumorigenesis and angiogenesis in vivo, and exerted its functions partly 
through one of its downstream target ADAM 17, a disintegrin and metaloprotease 17 























































































































































































































































































































































































































































































































































































1.5 Hypothesis and Aims of the Study 
Since previous studies have established the pivotal role of microRNAs in HCC, 
we hypothesize that COOH-temiinal truncated HBx mediates its oncogenic effects 
through deregulating cellular miRNAs. The objectives of this study are (1) to detect 
full-length and COOH-temiinal truncated HBx in HCC tissues; (2) to investigate the 
biological effects of full-length and COOH-temiinal truncated HBx on cell 
proliferation, cell cycle progression and apoptosis; and (3) to identify and validate 
miRNAs that are regulated by different forms of HBx. 
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Chapter 2 MATERIALS AND METHODS 
2.1 Patients 
Twenty pairs of liver tumors and the matched nontumor adjacent tissues were 
collected from patients diagnosed with HCC during the curative surgery between 
2004 and 2006 at the Prince of Wales Hospital in Hong Kong. All patients were 
HBV-positive. Fifteen patients had liver cirrhosis while the remaining five patients 
did not. The availability of tissue slides, tissue DNA and RNA for study were 
indicated in Table 2.1. Two viral DNA samples, extracted from the serum of patients, 
CH230 and BC265, were taken for the PCR amplification of HBx gene for molecular 
cloning. 
2.2 Cell Lines 
An immortalized non-tumorigenic human liver cell line, MIHA (described in 
Brown et al., 2000) and 293T human embryonic kidney (HEK) cells (obtained from 
American Type Culture Collection) were cultured in Dulbecco’s modified Eagle's 
medium (DMEM) (Gibco) supplemented with 10% Fetal Bovine Serum (FBS) 
(Thermo Scientific HyClone). The cell lines were maintained at 37°C in a humidified 
incubator with 5% CO2. 
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Table 2.1 Demographic information of 20 patients diagnosed with HCC. The 
availability of clinical samples, including tissue slides, tissue DNA and RNA was 
marked as "+", present and absent. 
Availability Availability Availability 
of Tissue of Tissue of Tissue 
Case no. Sex Age HBV Cirrhosis Slides RNA DNA 
508 F 46 + + + + + 
512 M 48 + + + - -
513 F 39 + + + + + 
515 M 60 + + + + + 
519 M 52 + + + + + 
522 F 42 + + + + + 
527 M 59 + + + + + 
531 M 68 + - + + + 
532 M 71 + + + + + 
546 M 48 + - + - -
547 M 59 + - + + + 
548 M 56 + + + - -
550 M 67 + - + + + 
551 M 65 + + + + + 
552 M 58 + + + + + 
553 M 65 + + + - -
554 F 62 + + + + + 
557 M 64 + + + + + 
558 F 55 + + + + + 
559 M 53 + - + + + 
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2.3 Cloning of Various HBx Constructs 
2.3.1 PCR Amplification of HBx Fragments 
DNA fragments of full-length HBx were amplified by polymerase chain 
reaction (PCR) using the viral DNA extracted from the serum of patients, CH230 or 
BC265, or a plasmid pBR-HBadr4 (Araki et al., 1990), while COOH-temiinal 
truncated HBx fragments was amplified using viral DNA of CH230 as template. PCR 
was carried out by flanking the HBx template with a forward primer, with a Kozak 
consensus sequence (GCCACC) preceding the start codon (ATG) and a flag-tag 
DNA sequence (GATTACAAGGATGACGATGACAAG) at the N-terminal of the 
HBx sequence, and reverse primers with an artificial stop codon (TAA) at different 
HBx deletion sites (Table 2.2) (Knappik and Pluckthun, 1994). The present of a 
Kozak sequence (GCCA/GCCAUGG) preceding the start codon enhances the 
efficiency of translation initiation in eukaryotic cells (Kozak, 1987; Nakagawa et aL, 
2008). 
PCR amplification of various HBx fragments was carried out in two 25-|il 
reactions, including 2.5 jal of GeneAmp® 10X PCR Gold Buffer, 2 |al of MgCl2 
solution, 0.5j.il of 10 mM dNTP (MBI Femientas), 0.5 f.il of 10 ).iM Forward primer, 
0.5 of 10 jiM Reverse primer, 0.125 \x\ of AmpliTaq Gold® DNA Polymerase 
(Applied Biosystems), 2 j.il of viral DNA (CH230) and 16.875 jil of nuclease-free 
water, and incubated in the GeneAmp® PCR System 2700 Thermal Cycler (Applied 
Biosystems) at 95°C for 10 min, 35 cycles of 95�C for 30 s, 52°C for 30 s and 72°C 
for 1 min, and 72°C for 7 min. The PCR products were resolved by electrophoresis 
on a 1.5% (w/v) agarose gel stained with 2 (il of GelRed Nucleic Acid Stain (Biotium) 
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in 1 x TBE buffer (89 mM Tris-base，98 mM boric acid, 2 mM EDTA) and 
visualized with GelDoc XR (Bio-Rad Laboratories, Inc.). Targeted fragments were 
extracted using the Gel Extraction Kit (Qiagen) and eluted with 30 (.il of sterile water. 
2.3.2 Cloning of HBx Fragments into TA-vectors 
Cloning of PGR products was performed using the TOPO TA Cloning Kit 
(Invitrogen). A 6-|il reaction, containing 4 jil of PCR products, 1 jil of salt solution 
(1.2 M NaCl, 0.06 M MgCl2) and 0.5 \x\ of pCR2.1-TOPO or pcDNA™3.1/V5-His 
TOPO (10 ng/jil), were prepared and incubated at room temperature for 15 min. 
pCR2.1-X, pCR2.1-XA14, pCR2.1-XA35, T0P03.1-X, T0P03.1-XADR and 
T0P03.1-X265 were generated. 
2.3.3 Heat Shock Transformation 
Transformation was performed by adding all ligation products to a vial of E. 
coli competent cells, TOP 10. After incubating on ice for 15 min, the cells were heat 
shock at 42°C for 1 min, and then kept on ice immediately. The cells were recovered 
by 250 jil of S.O.C. medium (Invitrogen) and incubated at a 37°C shaker for 1 hour. 
Cells from each transformation were allowed to growth on a LB agar plate [1 % 
tryptone, 0.5 % yeast extract, 1% NaCl, 15% agar (pH7.0)] containing 0.1 mg/ml 
ampicillin, at 37 °C overnight. 
Colonies were allowed to grow in 3 ml of LB medium [1 % tryptone, 0.5 % 
yeast extract，1% NaCl] containing 0.1 mg/ml ampicillin at 37 °C overnight. Plasmid 
DNA was extracted by QIAprep Spin Miniprep Kit (Qiagen) and eluted by 50 jj! of 
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nuclease-free water. Nucleotide sequences and the orientation of the inserts were 
confirmed by DNA sequencing using BigDye® Terminator v3.1 Cycle Sequencing 
Kits (Applied Biosystems) and ABI PRISM® 3100 Genetic Analyzer. 
2.3.4 Sub-cloning of HBx Fragments into Lentiviral Vectors 
Various versions of HBx were sub-cloned to the EcoRl and Sail restriction sites 
of a lentiviral vector, pRRL-cPPT-CMV-X-IRES-EGFP-PRE-SIN (A gift from Prof. 
Chen) (Figure 2.1). Restriction digestion was carried out in a 30-|il reaction, 
including IX NEBuffer 3，IX bovine serum albumin (BSA) (10 j.ig/ml), 10 units of 
Sail restriction endonuclease (New England BioLabs Inc.), 12 units of EcoRl 
restriction endonuclease (Promega Biotech Co.，Ltd), 4 p.g of plasmid DNA 
(pCR2.1-X, pCR2.1-XA14 or pCR2.1-XA35) and nuclease-free water, for 4 hours in 
a 37°C incubator. The digested fragments were resolved in a 1.5% (w/v) agarose gel, 
and extracted using the Gel Extraction Kit (Qiagen) and eluted with 25 (il of sterile 
water. 
Ligation of the digested products and the lentiviral vector was earned out in a 
20-f.il reaction mixture, containing 1 X T4 DNA Ligase Reaction Buffer, 400 units of 
T4 DNA Ligase (New England BioLabs Inc.), 100 ng of digested lentiviral vectors 
and 16 fil of gel purified DNA fragments. The ligation reaction was carried out at 
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Figure 2.1 A schematic diagram of a lentivirus Vector, 
pRRL-cPPT-CMV-X-IRES-EGFP-PRE-SIN. Lentivirus transduction is 
characterized by its high infection efficiency, broad tropism and its ability to infect 
non-dividing cells or primary cell culture (Naldini et al,, 1996). A DNA copy of the 
viral RNA genome, the viral backbone with the insert, will integrate into the host 
cellular genome upon infection (Marshall et al., 2007). The third-generation 
lentivirus vector encodes a self-inactivating construct in the 3’ LTR to inactivate any 
production of wild-type lentivirus. Various versions of HBx fragments were PCR 
amplified and cloned into the EcoRI and Sail restriction sites of the lentivirus vector. 
Transcription of the target genes was driven by the CMV promoter. The IRES 
element permits the translation of the gene of interest and the EGFP gene from a 
single bicistronic mRNA. The transduction efficiency can be estimated by the 
percentage of EGFP-positive cells under a fluorescent microscope or by flow 
cytometry. 
Abbreviations: RSV, Rous sarcoma virus and HIV chimeric long terminal repeat; 
RRE, HIV Rev response element; cPPT, HIV-1 central polypurine tract; CMV, 
human cytomegalovirus; IRES, the internal ribosome entry site of the 
encephalomyocarditis virus; EGFP, enhanced green fluorescent protein; PRE, human 
hepatitis virus posttranscriptional regulatory element, LTR (AU3), deletion in the 
































































































































































































































































































































































































































































































































































































2.4 Generation of Lentivirus 
Packaging of lentivirus was performed by transient transfection of 293T human 
embryonic kidney cells with the lentivirus transfer vectors and three packaging vectors, 
pMDL/pRRE, pRSV-REV and pCMV-VSVG. The day prior to transfection, confluent 
10-cm plates of 293T cells were split 1:5 and maintained in DMEM supplemented with 
10% FBS at a 37°C incubator. A mixture of plasmids, including 10 jig of transfer 
vectors, 6.6 jig of pMDL/pRRE, 3.5 jig of pCMV-VSVG and 2.5 jig of pRSV-REV, 
was transfected to 293T cells by calcium phosphate method. Culture medium was 
removed a day after transfection. For an additional 24 hours, culture medium was 
harvested and the viral particles were concentrated by ultracentrifiigation at 700000 x g 
for 2 hours at 20°C. The viral pellets were resuspended in 100 |.il of 1 x HBSS and 
stored at -80°C (Tiscornia et al, 2006). 
2.4.1 Lentivirus Infection 
One day prior to infection, 2 x 104 of cells were seeded in wells of a 24-well plate 
and incubated in a 37°C incubator with 5% CO2. The medium was removed and 
replaced with 400 jal of fresh medium (DMEM supplemented with 10% FBS) with 8 
jj.g/ml polybrene (Sigma-Aldrich, Inc.) and lentivirus. Cells were transduced for 48 
hours, and the virus-containing medium was discarded, and washed twice with PBS to 
remove any residual virus. The transduction efficiency was monitored by a fluorescent 
microscope. The amount of virus used for each transduction was determined by the 
percentage of EGFP-positive cells by flow cytometry at day 3 post-infection. Three 
viral levels were tested. To ensure linearity, the percentage of EGFP-positive cells was 
compared only for the infection rate between 5 - 20%. 
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2.5 RNA Extraction 
Total RNA containing small RNA molecules was extracted using miRNeasy Mini 
Kit (Qiagen, Valencia, CA, USA) according to the standard protocol. In brief, cells were 
completely lysed by 1.4 ml of QIAzol, before mixing with 280 pi of chloroform. The 
homogenate was then centrifuged for 15 min at 12000 x g at 4°C to obtain the aqueous 
layer. Ethanol precipitation was carried out by mixing 750 [d of aqueous layer with 1.05 
ml of 100% ethanol. The mixture was transferred into an RNeasy Mini spin column, and 
centrifuge at 8000 x g for 30 s to drain off the flow-through. The RNA binding 
membrane was then washed with 350 jil Buffer RWT, incubated with DNase I (Qiagen, 
Valencia, CA, USA), and washed by 350 jal Buffer RWT again and followed by 500 jil 
Buffer RPE twice. Buffer RWT contained guaiiidine thiocyanate as the chaotrophic 
agent and ethanol as the organic solvent, which allowed efficient binding of RNA to the 
silica membrane of the spin column. Substances that bound non-specifically to the silica 
membrane could be washed away by ethanol without disturbing the RNA-membrane 
interaction. Thus, RNA of high yield and purity could be obtained after elution. Total 
RNA was recovered by eluting with 50 jil of RNA-free water. The purity and 
concentration of RNA were determined by NanoDrop 1000 spectrophotometer (Thermo 
Fisher Scientific Inc.). The RNA was stored at -80°C before use. 
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2.6 Western Blot Analysis 
Fifty micrograms of protein were resolved on a 15% SDS-PAGE. A PVDF 
membrane fAniersham Biosciences)，2 filter papers and the SDS-PAGE were 
equilibrated in a transfer buffer (39 mM glycine, 48 mM Tris-HCl, 0.037% SDS, 20% 
methanol, pH 8.3) before assembly in the Trans-Blot Semi-Dry Electrophoretic Transfer 
Cell (Bio-Rad Laboratories, Inc.). 
After blotting, the membrane was blocked in 5 ml of blocking buffer [PBST with 
5% (w/v) non-fat dried milk powder] at room temperature for 15 min. The membrane 
was probed with Hepatitis B Virus X antigen antibody [X36C] (ab2741) (Abeam pic) 
(1:2000) or anti-beta actin antibody (Santa Cruz Biotechnology, Inc.) (1:5000) at 4°C 
overnight, and then with anti-mouse antibodies conjugated with horseradish peroxidase 
(1:5000) (Santa Cruz Biotechnology, Inc.) at room temperature for 1 hour. The 
membrane was washed by 15 ml of PBST for 3 times. The blot was visualized with 
Western Lightning Chemiluminescence Reagent Plus (Amersham Biosciences) by 
exposing to the FUJI Medical X-Ray Film (FUJI) in a dark room. The film was 
processed by the developer and fixer. 
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2.7 MiRNA Microarray 
Agilent Human miRNA Microarray Kit (V2) (Agilent Technology) was used for 
miRNA profiling of various HBx-expressing MIHA cell lines and a mock-infected 
control. One hundred nanograms of total RNA，including small RNA, were taken for 
miRNA profiling. The concentration and purity of total RNA were determined by 
NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific Inc.) and the RNA 
integrity was determined by Agilent 2100 Bioaiialyzer (Agilent Technology). 
2.7.1 Cyanine3-pCp Labeling of RNA Samples 
The input RNA was dephosphorylated by Calf Intestine Alkaline Phosphatase (CIP) 
in a 7-jal reaction mixture, containing 0.7 fil of 10X CIP buffer, 0.7 |il of CIP (16 U/ 
(GE Healthcare), 4 jal of total RNA (25 ng/ jil) and 1.6 (il of nuclease free water, by 
incubating at 37°C for 30 min. The reaction mixture was flirther incubated with 5 (il of 
100% dimethyl sulphoxide (DMSO) at 100°C for 8 min, and kept on an ice-water bath 
for a further 3 min. 
Labeling of Cy-3 fluorescent dyes to 3' ends of miRNAs was carried out by mixing 
the 12 \i\ of dephosphorylated RNA with a 8-|il ligation master mix, including 2 jil of 
10X T4 RNA Ligase Buffer, 2 |.il of 0.1% BSA, 3 |il of Cyanine3-pCp (Cy3-pCp) and 1 
\x\ of T4 RNA Ligase (15 U/jil) (GE Healthcare). The resultant ligation mixture was 
incubated at 16°C for 2 hours. Micro Bio-Spin 6 column (Bio-Rad Laboratories, Inc.) 
was used to purify the labeled RNA, by loading a mixture of the 20-jil RNA sample and 
30 |il of RNase-Free water onto the gel bed of the column. The purified sample was 
obtained as the flow-through by centrifuging the column for 4 min at 100 x g. 
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2.7.2 Sample Hybridization 
The purified sample was dried completely using a speed-vac at 45 °C, and was 
resuspended with 18 pi of nuclease-free water, followed by 4.5 \x\ of the 10X GE 
Blocking Agent and 22.5 pi of 2X Hi-RPM Hybridization Buffer. The sample mixture 
was kept at 100°C for 5 min, and then on ice for a further 5 min. The hybridization 
sample was slowly dispensed onto the gasket well in a "drag and dispense" maimer, and 
covered with a SureHyb chamber. The assembled slide chamber was installed in a 
hybridization oven with the rotor speed at 20 rpm at 55°C for 20 hours 
2.7.3 Microarray Wash 
The microarray wash procedure was carried out according to the conditions in 
Table 2.3. The Gene Expression Wash Buffer 2 was pre-warmed to 37°C the night 
before washing the arrays. 
2.7.4 Array Slide Scanning and Data Processing 
The microarray slide was scanned using an Agilent Microarray Scanner, and data 
was extracted using the Agilent Feature Extraction Software. Data analysis was 
performed on GeneSpring software (Agilent Technologies). Non-expression probes 

































































































































































































2.8 Detection of HBx Gene Deletion by PCR 
HBx gene deletion was detected by PCR using a universal forward primer (XF) 
and five different reverse primers (Rl, R2, R3，R4 and R5) flanking the full length and 
different lengths of HBx gene as stated by Ma et al. (Table 2.1). One hundred nanogram 
(lOOng) of DNA extracted from liver tumors and the matched non-tumor adjacent 
tissues was taken as templates for the amplification of various versions of HBx gene. 
PCR of human (3-actin gene was used as a loading control. A total volume of 25-p,l 
reaction mix was prepared according to the standard protocol of Promega GoTaq Fexi 
DNA polymerase [5 of5X Green GoTaq Fexi Buffer, 2 jil of 25 mM MgCl2, 0.5 \x\ of 
10 mM dNTP (Fermentas), 0.5 |.il of 10 |iM Forward primer, 0.5 jil of 10 jiM Reverse 
primer, 0.125 of GoTaq DNA Polymerase (5U/|.il), 100 ng of DNA template and 
nuclease-free water]. 
PCR was carried out in the GeneAmp® PCR System 2700 Thermal Cycler 
(Applied Biosystems) at 95°C for 2 min, 36 cycles of 95°C for 1 min, 62°C for 1 min 
and 72°C for 1 min, and 72°C for 7 min for the amplification of HBx genes, or 95°C for 
2 min, 28 cycles of 95°C for 30 s, 58°C for 30 s and 72°C for 30 s, and 72°C for 7 min 
for the amplification of p-actin gene. The PCR products were then analyzed by 
electrophoresis on a 1.5% agarose gel stained with GelRed Nucleic Acid Stain (Biotium) 
and visualized by GelDoc XR (Bio-Rad Laboratories, Inc.). 
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2.9 Immunohistochemistry 
Immunohistochemistry analysis was performed on 20 pairs of formalin-fixed and 
paraffin-embedded liver tissue sections, and 1 negative control section. Tissue sections 
were deparaffmized in Histolemon for 2 x 10 min and rehydrated through a graded 
alcohol series (100%, 95%,70%, H20) for 5 min. The slides were left at room 
temperature for 20 min, and then washed once in water. They were farther incubated in 
3% H2O2 for 5 min at room temperature for quenching of endogenous peroxidases, and 
washed twice in IX TBS. Non-specific bindings were blocked with 10% normal rabbit 
serum for 10 min. The endogenous HBx protein was stained by anti-Hepatitis B Virus, 
X-Protein, (MAB8429) a.a. 50-88，clone 146 (Minipore, Chemicon) (1:100 dilution) 
by incubating the slides at 4°C overnight. The slides were incubated with 
goat-anti-mouse antibody for 30 min at 37�C (1:100 dilution) and washed twice in IX 
TBS. The slides were incubated in peroxidase substrate solution for 5 min at room 
temperature. The reaction was blocked in water. The slides were counterstain with 
Hematoxilin for 15 s and were dehydrated through a graded alcohol series and mount 
with Eukitt (Ma et al.., 2008). 
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2.10 Quantitative Real-time PCR 
The level of mature microRNAs was quantified by TaqMan MicroRNA Assays 
(Applied Biosystems) (Table 2.4). Input total RNA was first diluted to 2ng/jj.l by 
nuclease-free water. Five nanograms (5ng) of total RNA were converted to cDNA by 
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) in a 7.5 \xl reaction 
volume. Five microlilter of reaction mix [0.075 jil of 100 mM dNTPs, 0.5 \x\ 
MultiScribe Reverse Transcriptase (50U/jil), 0.75 jil of 10X Reverse Transcription 
Buffer, 0.095 of RNase Inhibitor (20U/|il), 2.08 jil of nuclease-free water and 1.5 |il 
of miRNA-specific RT primer] together with 2.5 jil of total RNA (5ng) were prepared 
and incubated in the GeneAmp® PCR System 2700 Thermal Cycler (Applied 
Biosystems) at 16°C for 30 min, 42°C for 30 min and 85°C for 5 min. 
The quantitative PCR was carried out in a 384-well plate by Applied Biosystems 
7900HT Fast Real-Time PCR System. The 7.5 jal of reverse transcribed cDNA was 
diluted to 30 f.il by adding 22.5 f.d of nuclease-free water, and 2 |_il of the diluted product 
was taken as the input cDNA. A total volume of 10-|il reaction mix [5 |il of TaqMan 2X 
Universal PCR Master Mix (No AmpErase UNG), 1 jil of TaqMan MicroRNA Assay 
(20X), 2 of diluted Reverse transcription product and 3 of nuclease-free water] was 
prepared and PCR amplification was done at 95°C for 10 min, 40 cycles of 95°C for 10 
s and 60�C for 1 min. Data was normalized by U6 small RNA (RNU6B) and the fold 
change was determined by the comparative Ct method. All reactions were carried out in 







































































































































































































































































































































































































































































































































































































2.11 Proliferation Assay 
Cell viability was assessed by a colorimetric method using CellTiter 96® AQu e 0us 
One Solution Cell Proliferation Assay (MTS) (Promega Biotech Co., Ltd) for 5 
consecutive days. Two-thousand of cells were seeded to the wells of a 96-well plate 
in 100 (il of DMEM supplemented with 10% FBS in sextuplicate. The plate was kept 
in a 37°C humidified incubator before carrying out the MTS assay. Culture medium 
was discarded，and replaced with a 120-|il of MTS mixture, including 100 |il of fresh 
culture medium (DMEM with 10% FBS) and 20 |il of MTS solution. The plate was 
light-protected by covering with an aluminium foil and kept in a 37°C humidified 
incubator for 1 hour. The absorbance of the colorimetric products formed was 
measured at 490 nm by (iQuant Microplate Spectrophotometer (BioTek Instruments， 
Inc.). The background absorbance was subtracted from the wells of zero cells. 
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2.12 Cell Cycle Analysis 
Flow cytometry was employed to analyze the cellular DNA content. 
Approximately, 1 x 106 of cells were harvested by trypsinization and washed twice 
by PBS. After centrifugation, supernatant was discarded and cells were resuspended 
by 0.5 ml of cold PBS. For detecting GFP-containing cells, cellular proteins were 
cross-linked by mixing a further 500 of cold PBS buffered with 2% formaldehyde 
solution. A final cell suspension containing 1% formaldehyde was kept at 4°C for 1 
hour. After cross-linking, the formaldehyde-containing solution was removed by 
centrifugation, and the cell pellet was resuspended by 1 ml of PBS at room 
temperature. Ethanol permeablization of cells was carried out by adding 4 ml of 
ice-cold 70% ethanol to the cell suspension drop-by-drop while vortexing. The cell 
suspension was kept at 4°C for at least 12 hours before proceeding to propidium 
iodide (PI) staining. Staining buffer [PBS with 2% FBS] was used to wash the cell 
pellet after discarding the ethanol. The sample was resuspended by 1 ml staining 
buffer，and incubated with 500ug/ml of ribonuclease A (RNase A) (Invitrogen) at 
37°C for 30 min to eliminate cellular RNA. Sample DNA was stained with 10 jil/ml 
of PI (BD Phamiingen) at room temperature for an additional 30 min in the dark. 
Cellular DNA content was analyzed by BD FACSAria™ Flow Cytometer 
within 24 hours post-staining. Modfit LT 3.0 (Verity Software House) was used to 
conduct open-ends modeling of flow cytometry histograms, defining the position and 
the percentage of GoGi phases, S phases, and G2/M phases of cellular samples. 
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2.13 Annexin V Apoptosis Assay 
Cell apoptosis was assessed by flow cytometry using a PE Annexin V Apoptosis 
Detection Kit I (BD Phaimingen). The detection ultilized two fluorescent dyes, 
7-Amino-actinomycin D (7-AAD) and phycoerthrin (PE)-conjugated Annexin V, to 
differentiate viable cells from cells that underwent apoptotic or necrotic cell death. 
7-AAD was used to discriminate viable cells from non-viable cells, while 
phycoerthrin (PE)-conjugated Annexin V bound to the externalized membrane 
phospholipid phosphatidylserin (PS) that differentiate apoptotic or necrotic cells 
from viable cells (van Engeland et al” 1996; Zhang et al, 1997). 
One to two days before Annexin Y-PE and 7-AAD staining, 1 x of cells 
were seeded on a six-well plate. Culture medium was collected, and cells were 
harvested by trypsinization. The cells were washed twice by cold PBS, and 
resuspended with 100 jal of IX Annexin V Binding Buffer. The sample was incubated 
with 5 j.il of Aiinexoin V-PE and 5 jil of 7-AAD for 15 min at room temperature in 
the dark. An unstained control, a 7-AAD stained control, an Annexin V-PE stained 
control and a PE Annexin V and 7-AAD stained control were also set up to define the 
quadrants corresponding to viable cells, apoptotic and non-viable cells. 
EGFP-positive cells were gated for analysis. 
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2.14 Colony Formation Assay 
One day before transfection, 4 x 10，cells were seeded on a 6-well plate. 
Transfection mix included 94 \x\ of serum-free DMEM, 6 of FuGENE6 
Transfection Reagent (Roche) and 2 jig of plasmid DNA (T0P03.1-X, 
T0P03.1-XADR, T0P03.1-X265 and a control vector) was incubated for 20 min at 
room temperature and added drop-by-drop to the wells. Geneticin G418 (Invitrogen) 
(1000 jj,g/ml) were added to select transfected cells 48 hours after transfection. Fresh 
medium with 1000 jag/ml of G418 was replaced twice a week for a total of 14 to 18 
days. The colonies were stained with crystal violet (0.5% w/v) in methanol for 5 to 
10 min at room temperature. 
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2.15 Statistical Analysis 
Statistical analysis was performed by GraphPad Prism (GraphPad Software). 
Fisher's exact test was used to test the association between truncated HBx and HCC 
(Section 3.1). Mann Whitney U test was used to analyse the immunochemical scores 
(Section 3.2). Kappa analysis was used to assess the inter-observer agreement of the 
results of immunostaining (Section 3.2). Student's t test was used to analyse colony 
formation assay (Section 3.3)，cell proliferation (Section 3.4.3) and cell cycle 
analysis (Section 3.4.4). Wilcoxon signed rank test was used to compare the levels of 
HBx-deregulated miRNAs in clinical tissues (Section 3.5.3). P value < 0.05 was 
considered as statistically significant. Graphs were generated by SPSS (SPSS Inc.) or 
GraphPad Prism (GraphPad Software). 
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Chapter 3 RESULTS 
3.1 Detection of Full-length and COOH-terminal Truncated HBx in HCC 
Tissues 
To address whether the COOH-terminal deleted HBx was implicated in 
HBV-associated HCC, PCR amplification of various lengths of HBx was earned out 
in 16 pairs of HCC tissues and the matched adjacent nontiimor tissues. Five pairs of 
primers, a universal forward primer (XF) and five different reverse primers (Rl, R2, 
R3, R4 and R5), encompassing the full length and various lengths of HBx gene were 
used as described (Ma et al,, 2008) (Figure 3.1a). Equal quantity of DNA was taken 
for PCR amplification of HBx gene, and for the detection of relevant PCR bands 
(Figure 3.1b). For full-length HBx, it was detected in all adjacent non-tumor tissues 
(16/16) and 50% (8/16) of HCC tissues. For COOH-terminal truncated HBx, it was 
present exclusively in HCC tissues. It suggested that COOH-terminal truncated HBx 
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Figure 3.1 PCR amplification of HBx genes in tissue samples, (a) PCR analysis 
of COOH-terminal deletion in HBx gene. The forward primer XF encompassed the 
promoter region of HBx and the 5 different reverse primers at the C-terminal regions 
of HBx. (b) Representative figures of the PCR amplification of full-length HBx and 
truncated HBx by primer F1R1, F1R2, F1R3, F1R4 and F1R5 were shown. “N”， 














































































































































































































































































































































































3.2 Confirmation of HBx Expression in HCC Tissues 
The expression of HBx protein was confirmed by the immunohistochemical 
staining using a monoclonal anti-HBx antibody (Millipore, Chemicon, MAB8429) 
targeting the 50 - 88 aa of HBx domain. By recognizing the central domain, the 
anti-HBx antibody could interact with full-length and various forms of truncated 
HBx. In this regard, the intensity of HBx staining reflected the total amount of 
full-length and various forms of truncated HBx and could not differentiate their 
expression. A HBV-negative liver tissue was included as a negative control (Figure 
3.2). 
The immimostaining results were scored by three independent observers based 
on (a) the percentage of staining area, which was defined as grade 2 for 5 - 30% 
coverage, grade 3 for 30 - 60% coverage and grade 4 for > 60% coverage，(b) and the 
intensity of the staining signal, which was defined as weak (grade 1)，moderate 
(grade 2) and strong (grade 3) (Figure 3.3). A moderate agreement was achieved 
among the three independent observers (Table 3.3). Interestingly, both of the staining 
area and staining intensity in HCC tissue sections were significantly smaller and 
weaker than the tumor adjacent tissues (n = 20,p < 0.05) (Table 3.2). In addition, the 
two scoring parameters were not differed between the group of full-length HBx and 
COOH-temiinal truncated HBx samples (Table 3.4). The difference in the staining 
area and signal intensity could not be attributable to the binding affinity of the 
anti-HBx antibody to the HBxAg, as no observable gene deletion was detected on the 
50 - 88 aa of HBx domain. The results suggested that the expression level of HBx in 
HCC was lower than the adjacent non-tumor tissues. 
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Figure 3.2 Immunohistochemical staining of liver tissue sections. The tissue 
sections were stained with anti-HBx antibody. (A) Negative Control, tissue section of 
a HBV-negative patient; (B) Positive control, tissue section of a HBx-positive 
patient. 
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Table 3.2 Statistical analysis of immunochemical scoring based on the 
percentage of stained area and the staining intensity. Scoring of the 20 pairs of 
liver tissue sections was performed by three independent observers (A, B and C). 
(p-value, by Mann Whitney U test) 




Area 3 (2-4) 4 (2-4) 0.047 
Intensity 1 (1-3) 2(1-3) 0.045 
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Table 3.3 Inter-observer agreement (Kappa analysis). Moderate agreement on 
the immunochemical scoring was achieved between three independent observers (A, 
B and C). Indicated were the kappa values (0 -1 ) . 
A v s B A v s C B v s C 
Area 0.65 0.70 0.48 
Intensity 0.65 0.69 0.72 
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Table 3.4 Comparison of the staining area and staining intensity between the 
full-length HBx tissues and the truncated HBx samples, (p-value，by Mann 
Whitney U test) 
Truncated HBx Full length HBx 
(n=8) (n 二 24) P 
Median score 
(range) 
Area 3(2-4) 4(2-4) 0.322 
































































































































































































































































































































3.3 Comparsion of HBx from Different HBV Strains 
As COOH-terminal truncated HBx was often detected in liver tumors, we next 
aimed to investigate its biological significance in hepatocarcinogenesis. HBx from 
two viral strains, HBV genotype B and genotype C，were first compared, as sequence 
variation on the HBx genes might show different oncogenic potential. 
To estimate the oncogenic effects of HBx, colony formation assay was carried 
out on a non-tumorgenic hepatocyte cell line, MIHA, by transfecting HBx derived 
from two viral strains, HBV genotype B (BC265) and genotype C (CH230). In 
addition, HBx obtained from HBVADR, which had been demonstrated to induce 
HCC ill HBx-traiisgenic mice, was served as a reference (Araki et aL, 1990; Kim et 
al, 1991). 
Consistent to previous reports, all HBx-transfected cells had lower colony 
forming ability than the control cells (p < 0.01) (Figure 3.4a). Moreover, HBx 
derived from HBV genotype C, CH230 and HBVADR, had higher colony forming 
ability than HBx obtained from HBV genotype B, BC265 (p < 0.05) (Figure 3.4b). 
However, the mean number of colonies was not significantly different between HBx 
derived from CH230 and HBVADR (p = 0.49). Phylogenic analysis of the HBV 
sequence confirmed that both HBVADR and CH230 were belonged to HBV 
subgenotype Ce, which had been implicated in higher risk of HCC (Chan et aL, 2008) 
(Figure 3.5), Overall, HBx gene of HBV genotype Ce (CH230) might show stronger 
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Figure 3.4 Colony Formation Assay. Full-length HBx derived from HBV 
genotype B, BC265, and HBV genotype C, CH230 and ADR, were compared on 
their ability to form colonies, (a) Pictures from a representative set of experiment. 
The colonies were stained by crystal-violet in methanol, (b) Experiment was 
performed in three replicates and the results were presented by the mean and SD. “*” 
indicatedp < 0.05，and "**" indicatedp < 0.01 
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Figure 3.5 A phylogenic tree of two HBV subgroups, Cs and Ce. Classification 
of HBV genotype and subgenotype was based on the phylogenic analysis of 
complete viral sequences with reference to a group of HBV sequences of known 
genotypes using Phylip software version 3.68 (Felsenstein, 2008). 
http://evolution.genetics.washington.edu/phylip.html 
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3.4 Functional Characterization of COOH-terminal Truncated HBx 
3.4.1 Selection of COOH-terminal Truncated HBx 
As mentioned in the introduction, no truncation hot-spot was identified so far 
and the mechanism of C-temiinal deletion is still unclear. HBx truncation might be a 
random event, and the extend of truncation seemed to vary among samples. 
Two deletion constructs, HBxA14 and HBxA3 5, with 14-aa or 35-aa less from 
the C-terminus were designed for the in vitro studies (Figure 3.6). A previous study 
showed that the last 14-aa was a growth suppressive domain of HBx. Deletion of the 
last 14-aa could abrogate the growth suppressive effects induced by full-length HBx 
and effectively promote cell transformation, but its transactivition capability was still 
preserved (Tu et a\., 2001). On the other hand, deletion of the last 35-aa was 
identified as a natural mutant in clinical specimens (Xu et al,, 2007). For these 
reasons, a full-length HBx, two C-terminal truncated HBx constructs, HBxA14 and 
HBxA3 5, were constructed from HBV genotype C, and their biological effects were 

































































































































































































































































































































































































































































































































































3.4.2 Generation of Various HBx-expressing Hepatocyte Cell Lines 
The biological effects of various versions of HBx were investigated by 
transducing an immortalized，non-tumorigenic hepatocyte cell line, MIHA, with 
Lenti-X, Lenti-XA14, Lenti-XA35 and a mock-control. Lentiviral infection was 
characterized by high transduction efficiency and stable transgene expression as a 
result of viral integration into the host genome. The transduction efficiency was 
estimated to be around 70% to 90% by a fluorescent microscope at day 3 
post-infection (Figure 3.7). Cell sorting was performed to enrich the EGFP-positive 
population. Western blot analysis confirmed the expression of full-length HBx and 
C-teraiinal deleted HBx mutants, using a mouse monoclonal anti-HBx antibody 
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Figure 3.8 Western-blot of MIHA cell line transduced with various versions of 
HBx. (1) MIHA, (2) Empty vector, (3) Full-length HBx, (4) HBxA14 and (5) 
HBxA35. 
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3.4.3 Effect of Full-length and COOH-terminal Truncated HBx on Cell 
Proliferation 
To investigate whether various forms of HBx affected cell growth, a 
colorimetric method was used to measure the viability of lentiviral-infected MIHA 
cells expressing HBx, HBxA14 and HBxA35, and mock-infected control for 5 
consecutive days (Figure 3.9). 
The growth of full-length HBx-infected cells was significantly decreased when 
compared with mock-infected cells (p < 0.05) on day 4 and remained slower on day 
5. Throughout the period of investigation, the growth of HBxA14-infected cells was 
similar with the mocked-infected cells. In contrast, the proliferation of 
HBxA3 5-infected cells was significantly increased when compared with both 
full-length and mock-infected cells on day 5 (p < 0.05). Consistent to previous 
reports, the COOH-terminal deleted HBx mutants effectively abrogated the growth 
suppressive effect induced by full-length HBx, and the 35-aa deleted HBx even 
promoted cell proliferation. 
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Figure 3.9 Cell viability of MIHA cells induced by various forms of HBx for 5 
days. A background-corrected absorbance at 490 nm was shown. At least six 
replicates were included in each experiment. Results represented the mean and SD of 
2 independent experiments. “*” indicatedp < 0.05. 
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3.4.4 Effect of Full-length and COOH-terminal Truncated HBx on Cell Cycle 
To determine whether COOH-terminal truncated HBx promoted cell 
proliferation by altering the cell cycle, cellular DNA content of various 
HBx-expressing MIHA cells was analyzed by flow cytometry. The DNA content of 
active replicating cells is between G0/G1 phase and G2/M phase, as cell proliferation 
is usually accompanied with increased DNA synthesis and replication. Therefore, the 
percentage of proliferating cells can be quantified by the proportion of cells in S 
phase. 
Consistent with the cell growth result, the percentage of HBxA3 5-expressing 
cells in S phase was significantly greater than the mock-infected control (45.37% 士 
2.77% vs 38.18% 土 2.69%, p < 0.05) (Figure 3.10 and Figure 3.11). In contrast, 
full-length HBx-infected cells had greater proportion of cell in G0/G1 phase than the 
mocked-infected control (58.01% 土 2.14% vs 44.73% 土 5.69%, p < 0.05), while the 
percentage of S phase cells was lower than its truncated mutants and the 
mock-infected control (p < 0.05). Overall, COOH-truncated HBx might stimulate 
cell growth by promoting cells to the S phase, whereas the full-length HBx might 
inhibit cell proliferation by causing G0/G1 arrest. 
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Figure 3.10 DNA histograms of various versions of HBx expressing MIHA. 
Shown here were the representative figures of a set of experiment. EGFP-positive 
cells were gated for analysis. The histogram modeling was performed by Modfit LT 
(Verity Software House). The G0/G1 phase and the G2/M phase were indicated by 2n 
and 4n respectively, whereas the S phase region was shaded. The proportion of cells 
in G0/G1 phase, S phase and G2/M phase were shown in Figure 3.9. 
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Figure 3.11 Cell cycle analysis of various HBx-infected MIHA cells. Shown 
here were the mean and SD of 3 independent experiments. indicatedp < 0.05. 
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3.4.5 Effect of Full-length HBx and COOH- terminal Truncated HBx on 
Apoptosis 
To address whether various HBx-expressing cells promoted apoptotic cell death, 
flow cytometry was employed to detect apoptosis using Annexin V assay. The early 
apoptosis was defined as the percentage of cells in Quadrant Q4 (7-AAD negative 
and Annexin V-PE positive) and the late apoptosis was defined as the percentage of 
cells in Quadrant Q2 (7-AAD positive and Annexin V-PE positive) (Figure 4.12). 
The basal level of apoptosis and necrosis was considerably low in MIHA cell line. In 
general, the percentage of early apoptotic cells were below 2%, while the percentage 
of the sum of early apoptotic cells and late apoptotic cells were less than 5% in the 
three HBx-expressing cells and the mock-infected control, suggesting that the effect 
of HBx on apoptosis might be mild in basal condition (Figure 3.12). 
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Figure 3.12 Assessment of eary stage apoptosis by Annexin V assay. Cell 
apoptosis was assayed using Annexin V by flow cytometry. An unstained control, a 
7-AAD stained control and a Annexin V-PE stained control were set up to define 
quadrants corresponding to viable cells, apoptotic cells and necrotic cells. Quadrant 
Q2, late stage apoptotic cells or necrotic cells (7-AAD positive and PE-conjugated 
Annexin V positive); Quadrant Q3, viable cells (7-AAD negative and PE-conjugated 
Annexin V negative); Quadrant Q4, early apoptotic cells (7-AAD negative and 
PE-conjugated annexin V positive). EGFP-positive cells were gated for analysis of 
the percentage of apoptotic events. 
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3.5 MicroRNA Profiling of Various HBx-expressing Hepatocyte Cell Lines 
3.5.1 Identification of Deregulated MicroRNAs by Microarray 
In vitro studies showed that COOH-terminal truncated HBx stimulated cell 
proliferation and promoted the S phase progression of a non-tuinorigenic liver cell 
line, MIHA. In contrast, full-length HBx- infected cells suppressed cell growth and 
caused G0/G1 phase arrest. It was hypothesized that full-length HBx and its 
COOH-truncated mutants might regulate different sets of genes, leading to distinct 
biological phenotypes. To address this issue, a comprehensive miRNA microarray 
profiling was conducted to compare the miRNAs deregulated by full-length or 
COOH-terminal truncated HBx. 
MiRNA profiling was conducted using an Agilent human miRNA microarray 
(V2) platform, containing feature probes of 723 human and 76 viral miRNAs (Sanger 
database v. 10.1). Total RNA extracted from full-length HBx and HBxA35- infected 
MIHA cells were taken for the microarray profiling, and the profiles were compared 
with the mock-infected control. GeneSpring software (Agilent Technology Ltd.) was 
used to extract, normalize and analyze the microarray data. A list of miRNAs 
deregulated by full-length HBx and HBxA35 was shown in Table 3.5. 
A total of 23 miRNAs were identified to be altered by full-length HBx and/ or 
HBxA35 by at least 2-fold. Fifteen miRNAs were up-regulated by full-length HBx 
while 5 miRNAs were down-regulated. For HBxA35- induced miRNAs, 1 miRNA 
was up-regulated while 5 miRNAs were down-regulated. MiR-19a and miR-19b 
were down-regulated while miR-23a was up-regulated by 2-fold or above by both 
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forms of HBx. These commonly deregulated miRNAs might be essential mediators 
of the functions of HBx. 
In order to identify the essential miRNAs that contributed to distinct biological 
phenotypes of the full-length and COOH-terminal truncated HBx, we put our 
emphasis on miRNAs that differentially expressed between full-length HBx and 
truncated HBx- infected cells. As no miRNAs was differentially expressed in 
full-length HBx and HBxA35- expressing cells by more than 2-fold, the filtering 
stringency was reduced to 1.5-fold. A total of 6 miRNAs were identified to be 
up-regulated by HBx but down-regulated by HBxA35 (Table 3.6). 
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Table 3.5 A list of miRNAs deregulated by full-length HBx and HBxA35. The 





hsa-miR-122 3.47 1.47 
hsa-miR-365 3.13 0.71 
hsa-miR-125a-5p 2.65 1.16 
hsa-miR-193b 2.63 0.63 
hsa-let-7e 2.36 1.16 
hsa-miR-23a 2.33 2.07 
hsa-miR-222 2.27 1.06 
hsa-miR-27a 2.25 1.84 
hsa-miR-923 2.23 1.37 
hsa-miR-99b 2.23 1.18 
hsa-miR-768-3p 2.21 0.83 
hsa-miR-23b 2.12 0.94 
hsa-miR-186 2.11 0.75 
hsa-miR-34b* 2.06 0.78 
hsa-miR-29b-l* 2.01 1.5 
hsa-miR-210 1.98 0.25 
hsa-miR-30e 1.07 0.44 
hsa-miR-301a 0.7 0.46 
hsa-miR-18a 0.47 0.73 
hsa-miR-7-1* 0.45 1.04 
hsa-miR-19a 0.4 0.36 
hsa-miR-19b 0.4 0,48 
hsa-miR-19b-l* 017 0/71 
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Table 3.6 A list of miRNAs differentially expressed between full-length HBx 
and HBxA35 cells. The fold change was compared to the mocked-infected control. 
Cutoff: fold change > 1.5 or <0.67. 
Fold Change 
MicroRNA HBx/Vector HBxA35/Vector HBxA35/HBx 
hsa-miR-146a 1.86 0.65 0.35 
hsa-miR-210 1.98 0.25 0.13 
hsa-miR-26a 1.63 0.67 0.41 
hsa-miR-26b 1.55 0.62 0.40 
hsa-miR-30d 1.86 0.64 0.34 
hsa-miR-574-3p 1.63 056 0.34 
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3.5.2 Validation of Deregulated MiRNAs by Real-time PCR Analysis 
The microarray results were flirther validated by real-time PCR using TaqMan 
MicroRNA Assays. Eleven miRNAs were chosen for validation based on different 
expression patterns between full-length and truncated HBx- infected cells: (A) 6 
miRNAs with the same expression trend (miR-23a, miR-27a, miR-125a-5p and 
miR-99b were up-regulated by either flill-length or COOH-terminal truncated HBx 
by at least two-fold; miR-19a and miR-19b were down-regulated by either full-length 
and COOH-terminal truncated HBx by at least two-fold); (B) 3 miRNAs with 
differential expression patterns, up-regulated by full-length HBx but down-regulated 
by COOH-temiinal truncated HBx; (C) one miRNA undetectable by microarray 
(miR-190) and one was randomly chosen (miR-29c). 
Our validation study showed that the real-time PCR were consistent with the 
microarray results in 7 out of 10 miRNAs (70%) (Figure 3.13). This included the 6 
group A miRNAs, which had similar expression pattern between full-length HBx and 
truncated HBx, and 2 group B miRNAs, which showed opposite expression pattern 
between the two forms of HBx. For the remaining miRNAs, miR-29c, miR-193b and 
miR-365, opposite expression patterns were detected by real-time-PCR and 
microarray in full-length HBx or HBxA35- expressing cells, but the degree of 
disparity was relatively low. Besides, the expression of miR-190, which could not be 
detected by microarray, was detected by real-time PCR. This data suggested that the 
detection sensitivity of real-time PCR might be higher than those of microarray. In 
general, the microarray results could be validated by the real-time PCR, supporting 
the accuracy of the data (Figure 3.13). These miRNAs might represent some of the 



























































































































































































































































































































































































































































































































































































































































































































































































































































































3.5.3 Confirmation of Deregulated MiRNAs in HCC and Adjacent Non-tumor 
Tissues 
To test whether these deregulated miRNAs have functional relevance in human 
tumors, we measured their expression levels in 16 pairs of HCC and their matched 
adjacent non-tumor tissues. MiR-29c, miR-146a and miR-190 were selected for 
real-time PCR confirmation because they were differentially regulated by full-length 
HBx and truncated HBx. 
Interestingly, the expression levels of miR-29c, miR-146a and miR-190 were 
significantly lower in HCC compared to the adjacent non-tumor tissues (p < 0.001 to 
0.028) (Figure 3.14). Down-regulation of miR-146a was observed in 14 out of 16 
HCC samples, and among the 14 samples, the median fold change was 0.36 士 0.19. 
MiR-190 was down-regulated in 11 out of 16 HCC samples, and among the 11 
samples, the median fold change was 0.29 士 0.14. Furthermore, miR-29c was 
down-regulated in 12 out of 16 liver tumor samples and the median fold change was 
0.40 土 0.35. Overall, miR-29c, miR-146a and miR-190 were down-regulated by 
more than 2-fold in 37.5 — 62.5% of HCC samples, suggesting that these miRNAs 





1  -  ^c  ipi  2 




















 H  函適麵















 一  |
1
 ！
！一  竺譯-In  |一  |「|1  〒遅I 
咖们仍训记叨如碰抓咖棚啦咖抓棚咖 






























d 舰  I  一  一一
一























Figure 3.14 Confirmation of deregulated miRNAs in liver tissues. Real-time 
PCR was used to quantify the level of miR-29c, miR-146a and miR-190 in HCC 
tissues and the matched adjacent non-tumor tissues. The Ct values were normalized 
by RNU6B by comparative Ct method. "N" represents adjacent non-tumor tissue; 
“丁’，represents tumor tissue. The fold change was obtained by T/N. Statistical 
analysis was performed by Wilcoxon signed rank test. 
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3.5.4 Potential Downstream Targets of the HBx-deregulated MiRNAs 
To further explore the possible downstream targets, we employed two miRNA 
target prediction algorithms, TargetScan http://www.targetscan.org/ (Lewis et al., 
2005) and PicTar http://pictar.mdc-berlin.de/ (Chen et al., 2006). An overlapping 
feature shared by these two algorithms was constructed by miRGen 
http://www.diana.pcbi.upenn.edu/miRGen/v3/miRGen.html (Megraw et al,, 2006). 
Gene ontology of miR-146a was assisted by UniProt http://www.uniprot.org/. For 
miR-146a, we found that 157 target genes were predicted by TargetScan and 130 
genes were predicted by PicTar. Among them, 34 genes are in common between the 
two algorithms and 4 of them are related to cell growth and cell cycle, including 
SMAD4, NF2, PSMD3 and E1F5A2 (Figure 3.15a). For miR-190, 128 target genes 
were predicted by TargetScan while 86 genes were predicted by PicTar, and 68 genes 
are in common (Figure 3.15b). Among the 68 genes in common, PTCH, CDKNIB 
and HECA are involved in cell proliferation and cell cycle. Besides, 729 and 602 
target genes were predicted by PicTar and TargetScan respectively to be modulated 
by miR-29c (Figure 3.15c). A total of 448 predicted genes are shared by these two 
algorithms. Among them, 33 genes are taken part in cell proliferation and cell cycle, 
including CDK6, PTEN, CCND2, TGFB3, E2F7, etc. 
Quite a large number of genes regulated by miR-29c, miR-146a and miR-190 
were predicted to be involved in cell cycle and cell proliferation (Table 3.7). By 
validating the predicted miRNA targets, it might explain the distinct biological 
effects in full-length HBx and COOH-temiinal-trimcated HBx- expressing cells. 
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(A) miR-146a 
PicTar 34 TargetScaii 
\ \ genes i 
(B) miR-190 ^ ^ 
PicTar 53 TargetScan 
V\ genes / 
(C) miR-29c 
PicTar 443 TargetScan 
V\ genes i 
Figure 3.15 MiRNA targets predicted by PicTar and TargetScan. MiR-146a, 
miR-190 and miR-29c were taken for miRNA target prediction using 2 different 
algorithms. An intersection of these two pools of genes was identified by miRGen. 
Cell cycle and cell proliferation related genes were identified by gene ontology. 
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Table 3.7 Genes involved in cell proliferation and cell cycle. Among the 
common target genes predicted by TargetScan and PicTar，a number of them were 
involved in cell proliferation and cell cycle, and were determined by gene ontology, 
(a) Target genes of miR-146a; (b) target genes of miR-190; and (c) target genes of 
miR-29c were listed. 
(a) Target genes of miR-146a 
Gene Symbol Description 
SMAD4 SMAD family member 4 
EIF5A2 eukaryotic translation initiation factor 5A2 
NF2 neurofibromin 2 (merlin) 
PSMD3 proteasome (prosome, macropain) 26S subunit, non-ATPase, 3 
(b) Target genes of miR-190 
Gene Symbol Description 
PTCH Protein patched homolog 1 
CDKN1B Cyclin-dependent kinase inhibitor 1B 
HECA Headcase protein homolog (liHDC) 
(c) Target genes of miR-29c 
Gene Symbol Description 
ABLl Proto-oncogene tyrosine-protein kinase 
BTG2 BTG2 protein (NGF-inducible anti-proliferative protein PC3) 
CAV2 Caveolm-2. 
CCND2 Gl/S-specific cyclin-D2 
CDK6 Cell division protein kinase 6 
COL4A3 Collagen alpha-3(IV) chain precursor 
Beta-catenin-interacting protein 1 (Inhibitor of beta-catenin and 
CTNNBIPI 
Tcf- 4) 
DBCl Protein FAM5A precursor 
E2F7 E2F transcription factor 7 
EMPl Epithelial membrane protein 1 
FGA Fibrinogen alpha chain precursor 
GABl GRB2-associated-binding protein 1 
GAS7 Growth-arrest-specific protein 7 
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HBPl HMG box-containing protein 1 
HDAC4 Histone deacetylase 4 
INSIGl Insulin-induced gene 1 protein 
KLF4 Kj-ueppel-like factor 4 
LAMCl Laminin gamma-1 chain precursor 
MAP2K6 Dual specificity mitogen-activated protein kinase kinase 6 
MLLT7 Fork head domain transcription factor 
MXI1 MAX-interacting protein 1 
MYBL2 Myb-related protein B 
PCTK1 Serine/threonme-protein kinase 
PDGFB Platelet-derived growth factor B chain precursor 
PDGFC platelet-derived growth factor C precursor 
PMP22 Peripheral myelin protein 22 
PPM 1D Protein phosphatase 2C isofonn delta 
Apoptosis-stimulating of p53 protein 1 (Protein phosphatase 1 
PPP1R13B 
regulatory subunit 13B) 
Interferon-inducible double stranded RNA-dependent protein 
PRKRA 
kinase activator A 
Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-
PTEN 
specificity protein phosphatase PTEN 
PTP4A1 Protein tyrosine phosphatase type IVA protein 1 
SMPD3 Sphingomyelin phosphodiesterase 3 
TGFB3 Transforming growth factor beta-3 precursor 
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Chapter 4 DISCUSSION 
4.1 The Impact of COOH-terminal Truncated HBx in HCC 
Extensive research has been conducted on HCC, but the molecular mechanism 
is still poorly understood. One of the examples is the ambiguous role of full-length 
HBx on apoptosis. On one hand, full-length HBx was reported to induce apoptosis or 
sensitize cells to proapoptotic stimuli (Su et ah, 1997; Kim et a!..’ 1998; Berganietti 
et al.，1999; Liang et al.’ 2007). On the other hand, the X protein was found to 
prevent apoptosis or had no effect on apoptosis (Gottlob et a!., 1998; Kim et al., 
2001; Hodgson et al., 2008; Cheng et al,, 2008). Besides, HBx-mediated apoptosis 
might depend on the balance between cellular c-Myc and members of the NFKB 
transcription factor family (Su et al., 2001). Some researchers attempted to explain 
the growth suppressive effect of full-length HBx as a positive contributor to 
carcinogenesis. For instance, cell growth retarded by flill-length HBx facilitated viral 
replication (Ozer et al” 1996). Furthermore, full-length HBx could also inhibit DNA 
repair, enhancing its susceptibility to carcinogens (Prost et al, 1998; Jia et aL, 1999). 
In our study, HBx expression was examined in 20 pairs of HCC tissues and the 
matched adjacent non-tumor tissues by inummostaning. The inimunostaining scores 
suggested that the expression of HBx, including full-length and various forms of 
truncated HBx mutants, was lower in HCC than in adjacent non-tumor tissues. This 
was consistent with the immuiiostaining results by another group of investigators 
(Wang et al.’ 1991). It was found that HBV replication occurred only in adjacent 
non-tumor tissues but not in HCC tissues (Wang et al, 1991). In contrast, integrated 
HBV was more frequently observed in HCC than in adjacent non-tumor tissues (Lai 
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et al.，1988). As a result, it was suggested that the HBx expression in HCC might be 
contributed mainly by the integrated HBV, which had much lower copy number than 
the free HBV form (Wang et al., 1991). This finding may explain the low HBx 
expression in HCC than in adjacent non-tmnor tissues. 
Previous reports suggested that full-length HBx was strongly associated with 
HCC development, but its controversial effects on tumorigenesis, including growth 
retardation and apoptosis, causing one to doubt its role in HBV-related HCC (Unsal 
et al，1994). Moreover, we detected the COOH-terminal truncated versions, instead 
of full-length HBx, in 50% of HCC specimens, implying that the truncated forms of 
HBx are more relevant in HBV-associated HCC. Our results confirmed that 
full-length and COOH-terminal truncated HBx demonstrated distinct biological 
effects on a non-tumorgenic liver cell line. While full-length HBx suppressed cell 
proliferation and induced GO/Gl arrest, COOH-terminal truncated HBx abrogated 
the growth suppressive effect induced by full-length HBx. A certain form of the 
truncated mutants stimulated cells proliferation and promoted S phase progression. 
The difference in the biological phenotypes between full-length and 
COOH-terminal truncated HBx might be contributed by their subcellular localization 
ill liver cells determined by immimofluoresence. One reported showed that 
full-length HBx was localized in the cytoplasm, whereas HBx mutants with 7-aa to 
65-aa delected from the C-terminus were mainly localized in the nucleus (Bock et a!., 
2008). As a result, the effect of COOH-temiinal truncated HBx on the activation of 
certain signal transduction pathway, including Ras-Raf-MAPK, would be diminished 
(Doria et al., 1995). In constrast, the transcriptional regulation mediated by truncated 
HBx might be enhanced due to its nuclear localization. These findings provided 
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biological insight into the mechanism of action of COOH-terminal truncated HBx. 
As a whole, COOH-terminal truncated HBx might play a direct role in HCC. 
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4.2 The Biological Significance of COOH-terminal Truncated HBx Induced 
MiRNAs 
MiRNAs have been implicated in the development of various cancers, including 
liver, breast and lung cancer (Dalmay and Edwards, 2009). Certain tumor suppressor 
genes or oncogenes were deregulated by these small RNA molecules by 
post-transcriptional regulation. To better understand how miRNA mediates its effects 
on tumorigenesis, it is essential to find the downstream targets. 
We found that certain miRNAs were deregulated in cells expressing 
COOH-terminal truncated HBx and in HCC specimens, including miR-29c, 
miR-146a and miR-190, but their roles in HCC are not currently understood. 
Individual reports suggested that down-regulation of miR-29 was strong associated 
with HCC and NPC (Su et al., 2009; Sengupta et al., 2008). As an antiproliferative 
and pro-apoptoic miRNA, it was confirmed to regulate the expression of a 
transcription factor, YYl (Wang et al, 2008a), a DNA methyltransferase, DMNT3A 
(Fabbri el al” 2007), and apoptosis regulators, Mcl-l (Mott et al, 2007), CDC2 and 
p85 alpha (Park et a!.，2009). Deregulation of miR-29 might have a strong impact on 
gene regulation and cell survival. 
MiR-146a played a role in the regulation of immune response by targeting 
TRAF6 and IRAKI (Taganov et al., 2006). The oncoproteins of EBV and HTLV-1 
were found to stimulate the level of cellular miR-146a, possibly through activating 
N F K B (Motsch et al.’ 2007; Cameron et al, 2008; Pichler et al, 2008) . Interestingly, 
HBx could also activate NFKB to promote cell survival (Su et aL’ 1996; Yun et al” 
2002; URN et al., 2007). It might suggest a possible linkage between HBx, NFKB and 
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miR-146a in HBx-induced HCC. Though functional polymorphism of miR-146a was 
associated with HCC, its effect on hepatocarcinogenesis was not being investigated 
(Xu et al,, 2008). Evidences suggested that miR-146a might be implicated in cell 
proliferation and cancer metastasis. For instance, up-regulation of miR-146a was 
found to suppress breast cancer metastasis (Hurst et al” 2009). In leukemia cell lines, 
miR-146a retarded cell proliferation by inhibiting CXCR4 expression (Labbaye et aL, 
2008). 
MiR-190 was a member of the miRNA signature that differentiated 
HBV-infected livers from HCV-infected livers in a large scale miRNA profiling 
study (lira et aL, 2009). In addition, it was reported to be deregulated in HCC mice, 
but the current information on this miRNA was limited (Kutay et al., 2006). 
In addition to their biological impacts, there is increasing concern on the 
diagnostic and prognostic value of miRNAs. Being detected in the blood plasma or 
serum, miRNAs displayed a great potential as non-invasive biomarkers (Gilad et al” 
2008; Chen et al., 2008). Compared to niRNA, these tiny RNA molecules remained 
stable in the plasma or serum samples upon repeated freeze-and-flaw cycles or 
RNase treatment (Mitchell et al.’ 2008). 
Plasma miR-184 levels were significantly higher in patients diagnosed with 
squamous cell carcinoma of tongue compared with normal individuals (Wong et aL, 
2008b). In addition, quantification of plasma miR-92 levels allowed one to 
differentiate patients diagnosed with colorectal cancer from normal individuals with 
high sensitivity and specificity (Ng et al, 2009). Besides, circulating miRNAs were 
associated with pregnancy or certain disease states, including drug-induced liver 
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injury (Chim et a!.., 2008; Wang et al, 2009a). These studies suggested that miRNA 
might be a potential diagnostic marker of various cancers or disease states. 
In addition to its diagnostic potential, miRNA profiling of cancer patients was 
also displayed encouraging prognostic benefits. Prognosis and progression of 
patients with chronic lymphocytic leukemia could be inferred by simply a 13-miRNA 
signature (Calin et al” 2005). The prognostic efficacy of miRNAs was also suggested 
ill lung cancers (Yanaihara et al‘, 2006), colon adenocarcinoma (Schetter et al., 2008) 
and esophageal squamous cell carcinoma (Guo et a!.., 2008) 
MiRNA may also be a potential therapeutic target. This hypothesis had been 
testified by re-introducing miR-26a，a frequently downregulated miRNA in liver 
tumor tissues, into HCC transgenic mice induced by myc oncoprotein using 
Adeno-associated virus AAV infection (Kota et al, 2009). The apoptotic evenets 
mediated by miR-26a was observed in cancer cells, but not in nonmaligiiant 
heaptocytes. The tumor-selectivity demonstrated in this study strengthened our belief 
that miRNA might be a potential therapeutic option in cancer treatment. 
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4.3 Limitations of the Present Study 
Detection of COOH-terminal truncated HBx was carried out by PCR 
amplification using 5 sets of primers. The results were interpreted by the presence or 
absence of PCR bands after gel electrophoresis. In this way, we could not quantify 
the amount of truncated HBx or even determine the exact truncation sites of HBx in 
tissues. By using this qualitative approach, the discriminating power was satisfactory 
when the form of HBx in clinical samples was homogenous. However, it might fail 
to detect truncated variants of HBx in tissue specimens when full-length HBx 
co-existed, leading to false-negative results. 
This situation might be improved by iinmimohistocliemical staining of liver 
sections using two different anti-HBx antibodies, one targeting on the N-terminal 
domain or the central region of HBx protein, and the other recognizing the 
C-terminal domain (Ma et al, 2008). The present of truncated HBx might be 
justified by the staining pattern by the two antibodies. However, the COOH-targeting 
anti-HBx antibody is not commercially available and a time-consuming immunizing 
procedure is needed. 
Nevertheless, the sensitivity of PCR and inmiimohistochemical staining is still a 
limiting factor for detecting the minority population of HBx mutants. To enhance the 
detection limit, a high-throughput massive-parallel sequencing technology， 
pyrosequencing, can be employed (Thomas et ciL, 2006). By this technology, the 
presence of truncated HBx and the sites of truncation could be accurately detemiined 
and quantified in tissue specimens. 
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4.4 Future Studies 
To better understand the molecular mechanism of HBV-related HCC, the 
differential miRNA expression induced by full-length HBx and COOH-terminal 
truncated HBx should be further studied. Investigation can be carried out to elucidate 
the upstream pathway that deregulated HBx-induced miRNA expression, and the 
downstream biological effects of the HBx-induced miRNAs. To characterize the 
biological significance of these miRNAs, proliferation assay or cell cycle analysis 
will be investigated. Over-expression of miRNAs in cells expressing COOH-terminal 
truncated HBx will be performed to restore the biological effects. In addition, 
downstream targets of the altered miRNAs may be identified by utilizing the gene 
expression microarray and the existing miRNA target prediction programs. The 
potential targets will be further confirmed by luciferase reporter assays and western 
blot analysis. By further our study, we may better understand the mechanism of 
HBx-induced HCC. 
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Chapter 5 CONCLUSION 
COOH-terminal truncated HBx was detected and expressed in at least 50 % of 
HCC tissues, but not in the adjacent nontunior tissues. Distinct biological effects 
were observed in the two forms of HBx. For instance, COOH-terminal truncated 
HBx (HBxA35) stimulated cell proliferation possibly by promoting S phase 
progression, whereas full-length HBx inhibited cell growth via GO/Gl arrest. 
Furthermore, miRNA profiles showed that cells infected by HBx and HBxA35 
showed differential expression of some miRNAs. Concordantly, niiR-29c, miR146a 
and iiiiR-190 were down-regulated in HCC tissues compared to the adjacent tissues, 
suggesting that these miRNAs might be implicated in HBV-related HCC. 
In conclusion, our findings demonstrated the importance of COOH-terminal 
truncated HBx in HCC and explored the possible linkage between miRNAs and 
COOH-terminal truncated HBx- induced hepatocarcinogenesis. By understanding the 
biological effects and the downstream targets of the deregulated miRNAs, the 
mechanism of HBV-induced HCC will be more thoroughly dissected. 
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